Research programme: influenza virus vaccine intranasal - Shin Nippon Biomedical Laboratories

Drug Profile

Research programme: influenza virus vaccine intranasal - Shin Nippon Biomedical Laboratories

Alternative Names: TR-Flu

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Shin Nippon Biomedical Laboratories
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Influenza virus infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Influenza-virus-infections in Japan (Intranasal, Powder)
  • 12 May 2010 Preclinical trials in Influenza virus infections in Japan (Intranasal)
  • 12 May 2010 Immunogenicity data from a Preclinical trial in Influenza virus infections released by Shin Nippon Biomedical Laboratories
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top